Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shukui Qin
Observed name:
Qin, Shukui
Institutions:
Nanjing University of Chinese Medicine,
China Pharmaceutical University,
Nanjing General Hospital of Nanjing Military Command
Observed institutions:
Nanjing University of Chinese Medicine,
China Pharmaceutical University,
Nanjing General Hospital of Nanjing Military Command
ORCID:
0000-0003-2289-1521
Observed ORCID:
0000-0003-2289-1521
OpenAlex ID:
A5108313995
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
2026
·
Adam Yopp
, Minshan Chen
, et al.
·
Journal of Hepatology
·
75
Erdafitinib in Patients with FGFR- Altered Advanced or Metastatic Cholangiocarcinoma
2025
·
Shubham Pant
, Joon Oh Park
, et al.
·
Clinical Cancer Research
·
9
PDF
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.
2026
·
Peter Robert Galle
, Bruno Sangro
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
·
Cancer Research Communications
·
2
PDF
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
2026
·
Makoto Ueno
, Changhoon Yoo
, et al.
·
EClinicalMedicine
·
1
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)
2026
·
Thomas Yau
, Peter R Galle
, et al.
·
Future Oncology
·
1
PDF
Data from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table 1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Figure S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table 2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Figure S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table S3 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Table S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
Supplementary figure 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
2026
·
Shubham Pant
, Joon Oh Park
, et al.
Supplementary Data 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
2026
·
Shubham Pant
, Joon Oh Park
, et al.
Supplementary figure 2 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
2026
·
Shubham Pant
, Joon Oh Park
, et al.
Data from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
2026
·
Shubham Pant
, Joon Oh Park
, et al.
Supplementary figure 3 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
2026
·
Shubham Pant
, Joon Oh Park
, et al.
26 - Evaluación Global De La Calidad De Vida Relacionada Con Salud (cvrs) Y Valoración De La Eficacia En Pacientes Que Interrumpieron El Tratamiento Debido a Acontecimientos Adversos Relacionados Con El Tratamiento (aarts): Resultados Del Estudio Checkmate 9dw
2026
·
Bruno Sangro
, Thomas Decaens
, et al.
·
Gastroenterología y Hepatología
27 - Nivolumab Más Ipilimumab (nivo + Ipi) Frente a Lenvatinib O Sorafenib (len/sor) Como Tratamiento De Primera Línea (1l) En Carcinoma Hepatocelular Irresecable (chci): Eficacia En Pacientes Con Mal Pronóstico Y Seguridad Hepática En La Población Global Del Estudio Checkmate 9dw
2026
·
Bruno Sangro
, Thomas Decaens
, et al.
·
Gastroenterología y Hepatología
Chinese expert consensus on the management of adverse events to HER2-targeted antibody–drug conjugates in digestive system cancers (2025 edition)
2026
·
Yiyi Yu
, Jing Wu
, et al.
·
Clinical Cancer Bulletin
PDF
Additional file 3: Table S1. of Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
2017
·
Liu, Xinyang
, Qin, Shukui
, et al.
·
Figshare
Additional file 1: of Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
2016
·
Sun, Yan
, Cheng, Ying
, et al.
·
Figshare
Show more works
View as search
Works count:
25
Citation count:
89
H-index:
3
I10-index:
1
Year
Topic
Type